Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis

Sandra Camelo, Antonio H. Iglesias, Daehee Hwang, Brice Due, Hoon Ryu, Karen Smith, Steven G. Gray, Jaime Imitola, German Duran, Basel Assaf, Brett Langley, Samia J. Khoury, George Stephanopoulos, Umberto De Girolami, Rajiv R. Ratan, Robert J. Ferrante, Fernando Dangond

Research output: Contribution to journalArticle

217 Citations (Scopus)

Abstract

We demonstrate that the histone deacetylase (HDAC) inhibitor drug trichostatin A (TSA) reduces spinal cord inflammation, demyelination, neuronal and axonal loss and ameliorates disability in the relapsing phase of experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS). TSA up-regulates antioxidant, anti-excitotoxicity and pro-neuronal growth and differentiation mRNAs. TSA also inhibits caspase activation and down-regulates gene targets of the pro-apoptotic E2F transcription factor pathway. In splenocytes, TSA reduces chemotactic, pro-Th1 and pro-proliferative mRNAs. A transcriptional imbalance in MS may contribute to immune dysregulation and neurodegeneration, and we identify HDAC inhibition as a transcriptional intervention to ameliorate this imbalance.

Original languageEnglish (US)
Pages (from-to)10-21
Number of pages12
JournalJournal of Neuroimmunology
Volume164
Issue number1-2
DOIs
StatePublished - Jul 1 2005
Externally publishedYes

Fingerprint

trichostatin A
Histone Deacetylase Inhibitors
Autoimmune Experimental Encephalomyelitis
Multiple Sclerosis
E2F Transcription Factors
Myelitis
Messenger RNA
Histone Deacetylases
Demyelinating Diseases
Therapeutics
Caspases
Up-Regulation
Down-Regulation
Antioxidants
Growth
Pharmaceutical Preparations
Genes

Keywords

  • Experimental autoimmune encephalomyelitis
  • Histone deacetylase
  • Microarrays
  • Multiple sclerosis
  • Trichostatin A

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. / Camelo, Sandra; Iglesias, Antonio H.; Hwang, Daehee; Due, Brice; Ryu, Hoon; Smith, Karen; Gray, Steven G.; Imitola, Jaime; Duran, German; Assaf, Basel; Langley, Brett; Khoury, Samia J.; Stephanopoulos, George; De Girolami, Umberto; Ratan, Rajiv R.; Ferrante, Robert J.; Dangond, Fernando.

In: Journal of Neuroimmunology, Vol. 164, No. 1-2, 01.07.2005, p. 10-21.

Research output: Contribution to journalArticle

Camelo, S, Iglesias, AH, Hwang, D, Due, B, Ryu, H, Smith, K, Gray, SG, Imitola, J, Duran, G, Assaf, B, Langley, B, Khoury, SJ, Stephanopoulos, G, De Girolami, U, Ratan, RR, Ferrante, RJ & Dangond, F 2005, 'Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis', Journal of Neuroimmunology, vol. 164, no. 1-2, pp. 10-21. https://doi.org/10.1016/j.jneuroim.2005.02.022
Camelo, Sandra ; Iglesias, Antonio H. ; Hwang, Daehee ; Due, Brice ; Ryu, Hoon ; Smith, Karen ; Gray, Steven G. ; Imitola, Jaime ; Duran, German ; Assaf, Basel ; Langley, Brett ; Khoury, Samia J. ; Stephanopoulos, George ; De Girolami, Umberto ; Ratan, Rajiv R. ; Ferrante, Robert J. ; Dangond, Fernando. / Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. In: Journal of Neuroimmunology. 2005 ; Vol. 164, No. 1-2. pp. 10-21.
@article{608f03c975be4b0a8aa746f10d60f562,
title = "Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis",
abstract = "We demonstrate that the histone deacetylase (HDAC) inhibitor drug trichostatin A (TSA) reduces spinal cord inflammation, demyelination, neuronal and axonal loss and ameliorates disability in the relapsing phase of experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS). TSA up-regulates antioxidant, anti-excitotoxicity and pro-neuronal growth and differentiation mRNAs. TSA also inhibits caspase activation and down-regulates gene targets of the pro-apoptotic E2F transcription factor pathway. In splenocytes, TSA reduces chemotactic, pro-Th1 and pro-proliferative mRNAs. A transcriptional imbalance in MS may contribute to immune dysregulation and neurodegeneration, and we identify HDAC inhibition as a transcriptional intervention to ameliorate this imbalance.",
keywords = "Experimental autoimmune encephalomyelitis, Histone deacetylase, Microarrays, Multiple sclerosis, Trichostatin A",
author = "Sandra Camelo and Iglesias, {Antonio H.} and Daehee Hwang and Brice Due and Hoon Ryu and Karen Smith and Gray, {Steven G.} and Jaime Imitola and German Duran and Basel Assaf and Brett Langley and Khoury, {Samia J.} and George Stephanopoulos and {De Girolami}, Umberto and Ratan, {Rajiv R.} and Ferrante, {Robert J.} and Fernando Dangond",
year = "2005",
month = "7",
day = "1",
doi = "10.1016/j.jneuroim.2005.02.022",
language = "English (US)",
volume = "164",
pages = "10--21",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis

AU - Camelo, Sandra

AU - Iglesias, Antonio H.

AU - Hwang, Daehee

AU - Due, Brice

AU - Ryu, Hoon

AU - Smith, Karen

AU - Gray, Steven G.

AU - Imitola, Jaime

AU - Duran, German

AU - Assaf, Basel

AU - Langley, Brett

AU - Khoury, Samia J.

AU - Stephanopoulos, George

AU - De Girolami, Umberto

AU - Ratan, Rajiv R.

AU - Ferrante, Robert J.

AU - Dangond, Fernando

PY - 2005/7/1

Y1 - 2005/7/1

N2 - We demonstrate that the histone deacetylase (HDAC) inhibitor drug trichostatin A (TSA) reduces spinal cord inflammation, demyelination, neuronal and axonal loss and ameliorates disability in the relapsing phase of experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS). TSA up-regulates antioxidant, anti-excitotoxicity and pro-neuronal growth and differentiation mRNAs. TSA also inhibits caspase activation and down-regulates gene targets of the pro-apoptotic E2F transcription factor pathway. In splenocytes, TSA reduces chemotactic, pro-Th1 and pro-proliferative mRNAs. A transcriptional imbalance in MS may contribute to immune dysregulation and neurodegeneration, and we identify HDAC inhibition as a transcriptional intervention to ameliorate this imbalance.

AB - We demonstrate that the histone deacetylase (HDAC) inhibitor drug trichostatin A (TSA) reduces spinal cord inflammation, demyelination, neuronal and axonal loss and ameliorates disability in the relapsing phase of experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS). TSA up-regulates antioxidant, anti-excitotoxicity and pro-neuronal growth and differentiation mRNAs. TSA also inhibits caspase activation and down-regulates gene targets of the pro-apoptotic E2F transcription factor pathway. In splenocytes, TSA reduces chemotactic, pro-Th1 and pro-proliferative mRNAs. A transcriptional imbalance in MS may contribute to immune dysregulation and neurodegeneration, and we identify HDAC inhibition as a transcriptional intervention to ameliorate this imbalance.

KW - Experimental autoimmune encephalomyelitis

KW - Histone deacetylase

KW - Microarrays

KW - Multiple sclerosis

KW - Trichostatin A

UR - http://www.scopus.com/inward/record.url?scp=20444446595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444446595&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2005.02.022

DO - 10.1016/j.jneuroim.2005.02.022

M3 - Article

VL - 164

SP - 10

EP - 21

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -